As a result of the administration of ruxolitinib (a JAK1/2 selective kinase inhibitor) in mouse models, a decline in tumor cell proliferation rate was reported, showing a positive correlation between JAK1/2 and disease progression in KRAS-mutant NSCLC [120]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.